News and Trends 27 Apr 2017 Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […] April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Inside Labiotech 27 Apr 2017 Wait but why is Labiotech.eu based in Berlin? After “How do you make money,” that’s the question I am asked most. Here’s the answer for all the curious people out there! As you might already know, Labiotech.eu started in France. I was studying bioengineering with Joachim (the first guy I talked to on the first day of the first year!) at Sup’Biotech, and […] April 27, 2017 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
In Depth 27 Apr 2017 Spain: An Emerging Star in the European Biotech Community Take note, Spain is becoming a new hotspot for biotech in Europe. More than €400M of venture capital, counting recent fundraising and anticipated closings, is forecasted to be available this year to fund the creation and growth of start-ups in the life sciences sector. Behind the growing interest among investors are novel opportunities with breakthrough potential […] April 27, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2017 BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […] April 26, 2017 - 1 minutemin - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 26 Apr 2017 Infographic: Who’s who in the mRNA Therapeutics Field in Europe? The young field of mRNA therapeutics is booming and generating huge expectations. Which are the main players in Europe turning them into a reality? Therapies based on mRNA promise better vaccines and therapeutics by instructing the body to produce its own just by reading the instructions written in the RNA sequence. Thought for a long time to […] April 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 Novartis Negotiates its Way into the US Migraine Market Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […] April 25, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 EMA designates uniQure’s gene therapy for hemophilia a priority Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. The company recently has undergone several management shakeups and a strategy review, and it just made the decision to withdraw […] April 25, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 New Research could Save Patients from Graft-Versus-Host Disease A new study published in the journal Science Translational Medicine identifies a new treatment strategy to prevent GVHD after stem cell transplantation. Allogeneic stem cell transplantation remains one of the top treatments for blood cancers and inherited blood disorders, but the treatment is associated with a major risk of so-called graft-versus-host disease (GVHD). A new paper […] April 25, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2017 Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […] April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 24 Apr 2017 ‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for Mark Post is a researcher at the University of Maastricht and co-founder and CSO of Mosa Meat, the Dutch company that will bring the first lab-grown beef burger to the market. I asked him about his motivations and plans to make cultured meat a reality in the coming decade. Cultured meat is an animal-free, lab-grown […] April 24, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Apr 2017 Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […] April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2017 The World’s Most Expensive Drugs have European Owners A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare diseases bear the heaviest price tags – let’s have a look. While biotechs like Généthon and EspeRare are rethinking the high-risk high-profit model and looking to provide treatments at an affordable price, most rare disease meds on the market are among the most […] April 21, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email